Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

Sho Iketania Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA;b Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA

Lihong Liua Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

Manoj S. Naira Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

https://orcid.org/0000-0002-5994-3957

Abishek Chandrashekarc Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Hiroshi Mohria Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

Maple Wanga Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

Dan H. Barouchc Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA;d Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA;e Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA

Yaoxing Huanga Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

David D. Hoa Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA;b Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY, USA;f Division of Infectious Diseases, Department of Internal Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USACorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

We are grateful to the participants in this study for contributing to SARS-CoV-2 research. We thank Drs. Magdalena Sobieszczyk and Michael Yin for clinical assistance. There was no applicable funding for this study.

Disclosure statement

DHB reports receiving grants from Janssen and having a patent for COVID-19 vaccines licensed to Janssen (no premarket royalties or payments of any kind).

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

Information for

Open access

Opportunities

Help and information

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination

Acknowledgements

Disclosure statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature